A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms OSTRIA1; SOLO-1
- Sponsors AstraZeneca; AstraZeneca AB
- 13 Sep 2022 Results reporting overall survival data from 7-year of OS follow-up analysis presented at the 47th European Society for Medical Oncology Congress
- 09 Sep 2022 Overall Survival results With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation published in the Journal of Clinical Oncology
- 09 Sep 2022 Results presented in an AstraZeneca media release.